{
  "company": {
    "name": "Be Bio",
    "website": "https://be.bio/",
    "record": "https://startuphistory.org/c/be.bio"
  },
  "status": null,
  "history_since": "2021-03-04T12:46:49.000Z",
  "baseline": {
    "snapshot_id": "ff45cb78052c73c937e9d6cbc372f05a19ae7ddb04738fc1130aeaa9b1f80a6a",
    "observed_at": "2021-03-04T12:46:49.000Z",
    "headline": "B cell therapies | Be Bio | United States",
    "description": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
    "evidence": "https://web.archive.org/web/20210304124649/https://www.be.bio/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 0,
  "last_checked": null,
  "live_status": "offline",
  "messaging": [
    {
      "quote_observed_at": "2021-08-24T23:02:27.000Z",
      "variants": [
        {
          "headline": "B cell therapies | Be Bio | United States",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2021-03-04T12:46:49.000Z",
          "evidence": "https://web.archive.org/web/20210304124649/https://www.be.bio/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "B cell therapies | Be Bio | United States",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2021-08-24T23:02:27.000Z",
          "evidence": "https://web.archive.org/web/20210824230227/https://www.be.bio/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "B cell therapies | Be Bio | United States",
      "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
      "from": "2021-03-04T12:46:49.000Z",
      "to": "2021-08-24T23:02:27.000Z",
      "captures": 2,
      "evidence": "https://web.archive.org/web/20210824230227/https://www.be.bio/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2021-03-04T12:46:49.000Z",
          "to": "2021-08-24T23:02:27.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-06-14T16:32:40.000Z",
      "variants": [
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2022-07-05T02:33:41.000Z",
          "evidence": "https://web.archive.org/web/20220705023341/https://www.be.bio",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2023-01-27T11:58:07.000Z",
          "evidence": "https://web.archive.org/web/20230127115807/https://www.be.bio",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2023-09-29T01:09:43.000Z",
          "evidence": "https://web.archive.org/web/20230929010943/https://www.be.bio/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2024-01-05T01:21:29.000Z",
          "evidence": "https://web.archive.org/web/20240105012129/https://be.bio/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2025-01-15T14:54:33.000Z",
          "evidence": "https://web.archive.org/web/20250115145433/https://be.bio/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2025-07-14T06:34:26.000Z",
          "evidence": "https://web.archive.org/web/20250714063426/https://be.bio/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2025-07-24T14:01:39.000Z",
          "evidence": "https://web.archive.org/web/20250724140139/https://be.bio/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2026-01-16T22:20:20.000Z",
          "evidence": "https://web.archive.org/web/20260116222020/https://be.bio/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing our science with bold humanity",
          "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
          "observed_at": "2026-06-14T16:32:40.000Z",
          "evidence": "https://web.archive.org/web/20260614163240/https://be.bio/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Advancing our science with bold humanity",
      "subhead": "Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.",
      "from": "2022-07-05T02:33:41.000Z",
      "to": "2026-06-14T16:32:40.000Z",
      "captures": 9,
      "evidence": "https://web.archive.org/web/20260614163240/https://be.bio/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2022-07-05T02:33:41.000Z",
          "to": "2026-06-14T16:32:40.000Z"
        }
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Be Bio” company record, https://startuphistory.org/c/be.bio"
}